Upper Gastrointestinal Surgery, Department of Molecular Medicine and Surgery, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden.
Cancer and Translational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital, University of Oulu, Oulu, Finland.
Ann Surg Oncol. 2018 Sep;25(9):2693-2702. doi: 10.1245/s10434-018-6627-y. Epub 2018 Jul 9.
Gastric adenocarcinoma is the second most common cancer-related death globally. Assessing survival trends can help evaluate changes in detection and treatment. We aimed to determine recent prognosis trends in gastric non-cardia and cardia adenocarcinoma in an unselected cohort with complete follow-up.
Population-based nationwide cohort study, including 17,491 patients with gastric non-cardia adenocarcinoma and 4698 with cardia adenocarcinoma recorded in the Swedish Cancer Registry in 1990-2013 with follow-up until 2017. Observed and relative 5-year survival was calculated and stratified by resectional surgery and no such surgery. Prognostic factors were evaluated using multivariable Cox regression.
The relative overall 5-year survival remained stable at 18% for gastric non-cardia adenocarcinoma throughout the study period and increased from 12 to 18% for cardia adenocarcinoma. Concurrently, the proportion of patients who underwent resectional surgery decreased from 49 to 38% for non-cardia adenocarcinoma and from 48 to 33% for cardia adenocarcinoma. The relative postoperative 5-year survival increased from 33 to 44% for non-cardia adenocarcinoma and from 21 to 43% for cardia adenocarcinoma, whereas in nonoperated patients it decreased from 3 to 2% in non-cardia adenocarcinoma and increased from 3 to 5% in cardia adenocarcinoma. Poor prognostic factors were higher tumor stage, older age, and more comorbidity.
Despite decreasing resectional rates, the 5-year overall survival has remained unchanged for gastric non-cardia adenocarcinoma and improved for cardia adenocarcinoma over the last two decades in Sweden and is now similar for these sublocations. The postoperative survival has improved for both sublocations, but particularly for cardia adenocarcinoma.
胃腺癌是全球第二大常见癌症相关死亡原因。评估生存趋势有助于评估检测和治疗的变化。我们旨在确定在未选择的队列中具有完整随访的胃非贲门和贲门腺癌的近期预后趋势。
这是一项基于人群的全国性队列研究,包括 1990 年至 2013 年期间在瑞典癌症登记处记录的 17491 例胃非贲门腺癌和 4698 例贲门腺癌患者,随访至 2017 年。计算观察到的和相对 5 年生存率,并按切除术和无切除术进行分层。使用多变量 Cox 回归评估预后因素。
在整个研究期间,胃非贲门腺癌的相对总体 5 年生存率保持在 18%不变,而贲门腺癌则从 12%增加到 18%。同时,接受切除术的患者比例从非贲门腺癌的 49%降至 38%,从贲门腺癌的 48%降至 33%。非贲门腺癌的术后相对 5 年生存率从 33%增加到 44%,从贲门腺癌的 21%增加到 43%,而非手术患者的生存率从非贲门腺癌的 3%降至 2%,从贲门腺癌的 3%增加到 5%。较差的预后因素包括更高的肿瘤分期、更大的年龄和更多的合并症。
尽管切除术的比例下降,但在过去二十年中,瑞典胃非贲门腺癌的 5 年总体生存率保持不变,贲门腺癌的生存率有所提高,现在这两个部位的生存率相似。两个部位的术后生存率都有所提高,但贲门腺癌尤其如此。